TGIA
NTLA icon

Torrey Growth & Income Advisors’s Intellia Therapeutics NTLA Stock Holding History

Torrey Growth & Income Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
70,669
+122
+0.2% +$1.71K 0.4% 40
2026
Q1 		$886K Buy
70,547
+33,608
+91% +$428K 0.37% 45
2025
Q4 		$332K Buy
+36,939
New +$509K 0.12% 80

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Torrey Growth & Income Advisors's NTLA Position: Q2 2026 in Review

Torrey Growth & Income Advisors increased its Intellia Therapeutics (NTLA) stake by 0.17% in Q2 2026, buying an estimated $1.71K and bringing the position to 70,669 shares worth $1.18M. The position accounts for 0.4% of the portfolio, ranked #40.

Torrey Growth & Income Advisors first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Torrey Growth & Income Advisors held 70,669 shares of Intellia Therapeutics worth $1.18M as of Q2 2026.
  • Torrey Growth & Income Advisors bought 122 Intellia Therapeutics shares in Q2 2026, an estimated $1.71K.
  • Intellia Therapeutics made up 0.4% of Torrey Growth & Income Advisors's portfolio in Q2 2026, its #40 holding.
  • Torrey Growth & Income Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Torrey Growth & Income Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.